Nonbiological therapeutics are frequently used for the treatment of patients with rheumatoid arthritis (RA). Because the mechanisms of action of these therapeutics are unclear, the authors aimed to elucidate the molecular effects of typical antirheumatic drugs on the expression profile of RA-related genes expressed in activated synovial fibroblasts. For reasons of standardization and comparability, immortalized synovial fibroblasts derived from RA (RASF) and normal donors (NDSF) were treated with methotrexate, prednisolone, or diclofenac and used for gene expression profiling with oligonucleotide microarrays. The cytotoxicity of the antirheumatic drugs was tested in different concentrations by MTS tetrazolium assay. Genes that were differentially expressed in RASF compared to NDSF and reverted by treatment with antirheumatic drugs were verified by semiquantitative polymerase chain reaction and by chemiluminescent enzyme immunoassay. Treatment with methotrexate resulted in the reversion of the RA-related expression profile of genes associated with growth and apoptosis including insulin-like growth factor binding protein 3, retinoic acid induced 3, and caveolin 2 as well as in the re-expression of the cell adhesion molecule integrin α6. Prednisolone reverted the RA-related profile of genes that are known from inflammation and suppressed interleukins 1β and 8. Low or high doses of diclofenac had no effect on the expression profile of genes related to RA in synovial fibroblasts. These data give the first insight into the mechanisms of action of common antirheumatic drugs used for the treatment of arthritides. Synovial fibroblasts reflect the disease-related pathophysiology and are useful tools for screening putative antirheumatic compounds. (Journal of Biomolecular Screening 2007:328-340) 
INTRODUCTION
R HEUMATOID ARTHRITIS (RA) is a chronic, inflammatory autoimmune disease of unknown etiology that affects primarily the joints, with a variety of extra-articular manifestations. The main attribute of RA is a chronic inflammation in the synovial membrane and in the synovial fluid with infiltrating mononuclear cells from hyperplastic synovial tissue. Hyperplastic synovial tissue results from an increase in macrophage-like and fibroblast-like synoviocytes and from infiltration with T cells, B cells, plasma cells, and dendritic cells. As the disease progresses, the inflamed synovium leads to the formation of aggressive tumor-like pannus tissue that invades and destroys joint cartilage and bone. [1] [2] [3] Current therapeutic approaches focus on the suppression of inflammation, improvement of disease activity, and slowing the disease progression in RA. Therapeutics compose nonbiological compounds such as the disease-modifying antirheumatic drug (DMARD) methotrexate (MTX), the steroidal anti-inflammatory drug (SAID) prednisolone, and the nonsteroidal anti-inflammatory drug (NSAID) diclofenac. [4] [5] [6] Newer therapeutic strategies with biological response modifiers antagonize distinct inflammatory cytokines, for example, by administration of interleukin (IL)-1 receptor antagonist or anti-tumor necrosis factor (TNF) agents. 7, 8 In recent years, comprehensive data emerged from gene expression profiling of tissues and cells affected by RA. For instance, expression analysis of synovial tissue and fibroblasts with cDNA microarrays defined a molecular signature of RA that is suggested to be of diagnostic value classifying RA and osteoarthritis. 9 Because global gene expression analysis deepens the understanding of etiopathologic mechanisms underlying RA and other inflammatory autoimmune diseases, expression profiling is expected to lead to better diagnosis, patient classification, and individualized therapy. 10, 11 In particular, analyzing synovial tissue in RA is suggested to be of special importance for providing insight into disease progression and for monitoring the effectiveness of antirheumatic therapies. 12 However, comprehensive gene expression data about mechanisms of action of currently used antirheumatic therapeutics are limited.
With respect to the scarce information about frequently used antirheumatic drugs, we used SV40 T-antigen immortalized RA (HSE) and normal synovial fibroblasts (K4IM) as a model system to determine the expression profile of RA-related genes affected by antirheumatic treatment. The K4IM cell line expresses typical cell surface molecules, maintains the normal expression kinetics of early growth response 1 upon stimulation with synovial fluid of RA patients or TNF-α, induces HLA-DR after stimulation with interferon-γ, and represents normal, healthy synovial fibroblasts. 13 The synovial fibroblast cell line HSE was derived from a patient with RA (RASF) and expresses typical ILs such as IL1β, IL6, IL8, IL11, IL13, IL16, and IL18 as well as matrix degrading proteases (MMP1, MMP3, cathepsin B, and cathepsin L). 14 Therefore, HSE cells are considered a prototype of activated synovial fibroblasts.
In the present study, to gain insight into the mechanisms of action of frequently used drugs in RA, the molecular effects on RASF and synovial fibroblasts derived from normal donors (NDSF) before and after treatment with typical antirheumatic drugs were determined by gene expression profiling with oligonucleotide microarrays.
MATERIALS AND METHODS

Cell culture
The immortalized synovial fibroblasts HSE and K4IM were derived from primary synovial cells obtained from an RA patient (HSE) and from a normal donor (K4IM). 13, 14 Cells were cultured in RPMI 1640 (Biochrom, Berlin, Germany) supplemented with 10% human serum (German Red Cross, Berlin, Germany), 100 U/ml penicillin, 100 µg/ml streptomycin, and 18 µg/ml ascorbic acid at 37 °C, 5% CO 2 , and 90% humidity. Seventy-five percent of the culture medium was replaced every other day. Reaching 80% confluence, cells were trypsinized and replated at a density of 10,000 cells/cm 2 .
MTS tetrazolium assay
Synovial cells were plated at a density of 3000 cells per well of 96-multiwell plates. Reaching 70% confluence, the culture medium was replaced by 100 µl medium without phenol red containing different concentrations of MTX (0-1 µg/ml, Lantarel; Medac, Wedel, Germany), prednisolone (0-50 µg/ml, Solu-Decortin; Merck, Darmstadt, Germany), and diclofenac (0-150 µg/ml; Ratiopharm SF, Ulm, Germany) in triplicate. After 48 h, 20 µl MTS solution (2 mg/ml in phosphate-buffered saline; Promega, Mannheim, Germany) was added to each well for 3 h according to the manufacturer's instructions. Colorimetric measurement of formazan dye was performed on a spectrophotometer at 492 nm.
Gene expression profiling and data processing
Gene expression profiling was performed in duplicate. Reaching 80% confluency of the cells, the medium was removed, and cells were incubated for 36 h with medium containing 0.2 µg/ml MTX, 1 µg/ml prednisolone, 75 µg/ml diclofenac, or medium as control (n = 3 each). Total RNA was isolated using the QIAGEN RNeasy Mini Kit according to the manufacturer's protocols (QIAGEN, Hilden, Germany). Equal quantities of total RNA from each triplicate were combined and processed for HG-U133A microarray hybridization according to the manufacturer's recommendations. In brief, 5 µg of RNA was transcribed to cDNA and used to synthesize biotin-labeled cRNA. Ten micrograms of fragmented cRNA was hybridized to the HG-U133A GeneChips (Affymetrix, Santa Clara, CA) for 16 h at 45 °C. Raw gene expression data were processed 1) with GCOS 1.2 software (Affymetrix) according to the manufacturer's recommendations and 2) by robust multiarray analysis (RMA). 15 Genes were selected when reproducibly regulated >1.3-fold in HSE versus K4IM (n = 4 each), HSE treated with antirheumatic drugs versus HSE (n = 2 each), or K4IM treated with antirheumatic drugs versus K4IM (n = 2 each) as determined by RMA and GCOS 1.2.
To identify general mechanisms of action, those genes were selected that were consistently differentially expressed in HSE after 36 h of drug exposure in all pairwise comparison analyses using GCOS 1.2 (p ≤ 0.002667 for increased or p ≥ 0.997333 for decreased) and RMA signals (fold change >1.3 or <-1.3). The list of genes was submitted to the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to search objects in pathways. Log-transformed signal ratios of RMA data for all genes in the respective pathways were used to apply a color code for up-or down-regulation of individual genes.
PCR
Total RNA (5 µg) was reverse transcribed after annealing with 500 ng oligo-(dT) [12] [13] [14] [15] [16] [17] [18] oligonucleotides (Invitrogen, Karlsruhe, Germany) and 5U SuperScript reverse transcriptase (Invitrogen) in 70 µl as described by Gubler and Hoffman. 16 The relative expression level of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to normalize gene expression in each sample in different concentrations. Real-time PCR was performed in triplicate with 1 µl of single-stranded cDNA sample using the SYBR Green PCR Core Kit (Applied Biosystems, Foster City, CA) and the i-Cycler (Bio-Rad Laboratories GmbH, München, Germany). Relative quantitation of differentially expressed genes ( Table 1) is given as a percentage of the GAPDH product.
Chemiluminescent enzyme immunoassay
Supernatants of synovial cells treated with antirheumatic drugs or medium as controls were collected and stored at -20 °C.
Expression Profiling of Antirheumatic Drug Effects
IL1β and -8 were measured in duplicate by a quantitative chemiluminescent enzyme immunometric assay using the IMMULITE automated analyzer according to the manufacturer's instructions (DCP-Biermann, Bad Nauheim, Germany). In brief, the samples were diluted in medium and introduced along with alkaline phosphatase-coupled anti-IL antibodies into the test unit, which contained a polystyrene bead coated with monoclonal anti-IL antibodies. During incubation for 1 h at 37 °C, ILs are bound to form an antibody-sandwich complex. Unbound proteins are removed by a centrifugal wash. The chemiluminescent substrate is added, and the test unit is incubated for an additional 10 min. The photon output is proportional to the concentration of ILs.
RESULTS
Morphology of synovial cells and cytotoxicity of antirheumatic drugs
Synovial cells HSE (RASF) and K4IM (NDSF) displayed a typical fibroblast-like appearance ( Fig. 1) . For treatment of the cells with antirheumatic drugs, the in vitro drug concentration was deduced from the dose of the respective drug administered in RA patients. Compared with untreated RASF (Fig. 1A) and NDSF ( Fig. 1E) , treatment with 0.2 µg/ml of MTX resulted in a spindle-like morphology of RASF accompanied by a detachment of cells ( Fig. 1B) . NDSF treated with MTX ( Fig. 1F) took the shape, albeit to a lesser extent than RASF, of spindle-like fibroblasts. Upon administering 1 µg/ml prednisolone, RASF maintained a normal fibroblastic morphology with few cells floating in the medium (Fig. 1C) . Prednisolone had no effect on the morphology of NDSF ( Fig. 1G) . A high dose of 75 µg/ml diclofenac resulted in an elongation of RASF with few cells detaching and floating in the medium (Fig. 1D) . Diclofenac had no effect on the morphology of NDSF ( Fig. 1H) .
Cytotoxic effects of antirheumatic drugs on RASF and NDSF were determined by the MTS cytotoxicity assay (Fig. 2) . Treatment of synovial cells with MTX resulted in a decreased viability of RASF when applying 0.1 to 1.0 µg/ml MTX. NDSF tolerated doses of up to 0.2 µg/ml and showed a reduced viability upon treatment with high doses of MTX (0.5-1.0 µg/ml). Prednisolone had only minor effects on the viability of fibroblasts accompanied by a slight increase of metabolic activity in RASF. A slight decrease in RASF viability was apparent after treatment with 75 µg/ml diclofenac, which was prominent upon treatment with 100 to 150 µg/ml of the drug. Instead, NDSF showed cytotoxic effects as recently as after application of 100 to 150 µg/ml diclofenac. Treatment of cells with a clinically relevant dose of 10 µg/ml diclofenac had neither an effect on the morphology nor the physiological activity of RASF and NDSF (data not shown). Gene expression profiling was performed ble 1. Oligonucleotide Sequences
Accession Product Size Gene Name Gene Symbol Number Oligonucleotides (5′→3′) (Up/Down) (base pairs)
Glyceraldehyde- 3-phosphate dehydrogenase  GAPDH  NM_002046  GGC GAT GCT GGC GCT GAG TAC  149  TGG TTC ACA CCC ATG ACG A  Insulin-like growth factor binding protein 3  IGFBP3  NM_000598  GCA GCG CCG GCA GTG TGG AGA G  82  TTT GAA TGG AGG GGG TGG AAC TTG  Integrin α6  ITGA6  NM_000210  CAG GAC TTG AAA GAA ATG GTG AAT  143  ATA CAG ATA GGG GAG GAA ACA AAA C  Hypothetical protein MGC4655  MGC4655  NM_033309  GTG TCC ACG CGC CAG GGT AT  GGT CAC GCC ACT CGA TGT CAA A  211  Retinoic acid induced 3  RAI3  NM_003979  CAA ATT CCT GGG GCT GAT using doses that had either an effect on cell morphology or cell viability.
Gene expression profiling of synovial cells treated with antirheumatic drugs
Gene expression analysis of synovial fibroblasts resulted in 916 probe sets representing 739 genes that were reproducibly differentially expressed between RASF and NDSF (data not shown).
To identify genes that are regulated upon treatment with antirheumatic drugs and that may have an impact on RA, we focused on the 916 probe sets and determined genes that were differentially expressed in RASF treated with the respective antirheumatic drug ( Fig. 3 ; Table 2 ). Treatment of RASF with 0.2 µg/ml MTX resulted in differential expression of 29 genes (Fig. 3A) . Eleven of these genes were also differentially expressed in NDSF treated with MTX. Of special interest are 10 genes that were differentially expressed in RASF compared to NDSF and whose expression profile was reverted by treating RASF with MTX. These genes are known from cell growth and apoptosis-like insulin-like growth factor binding protein-3 (IGFB3), retinoic acid induced 3 (RAI3), DNA-damage-inducible transcript 4 (DDIT4), and caveolin 2 (CAV2). The genes deafness, autosomal dominant 5 (DFNA5), MGC4655, uridine phosphorylase 1 (UPP1), and sialyltransferase 7 (SIAT7E) are associated with cell metabolism, and integrin α6 (ITGA6) as well as cadherin type 4 (CDH4) play a role in cell adhesion and motility. Using prednisolone (1 µg/ml), 9 genes were differentially expressed in treated compared to untreated RASF (Fig. 3B) . Expression of IL1β and IL8, tissue factor pathway inhibitor 2 (TFPI2), lymphocyte antigen 96 (LY96), and the X (inactive)specific transcript reverted after treatment with prednisolone. Six of these 9 genes were also prednisolone-dependently regulated in NDSF. Treatment of RASF with 75 µg/ml diclofenac resulted in 6 differentially expressed genes (Fig. 3C) . One of these, transforming growth factor-β2 (TGFB2), known from cell growth and differentiation, was reverted to normal. In NDSF, none of those genes were differentially expressed.
Validation of gene expression profiles by reverse transcriptase PCR and immunoassay
To confirm the expression profiles that were determined by microarray analysis, differential expression of selected genes was analyzed by reverse transcriptase (RT) PCR (Fig. 4) . IGFBP3, ITGA6, MGC4655, RAI3, DDIT4, DFNA5, CAV2, and SIAT7E were confirmed as differentially expressed between RASF and NDSF and reverted, at least in part, upon application of MTX. The gene expression profiles of CDH4 and UPP1 could not be confirmed by RT-PCR (data not shown). TFPI2 was induced in RASF compared to NDSF and was repressed by prednisolone. LY96 was also induced by RASF, but its repression by prednisolone could not be confirmed. TGFB2, which was repressed in RASF after treatment with diclofenac as shown by microarray analysis, exhibited an increase in RASF compared to NDSF. RT-PCR did not show repression of TGFB2 in RASF upon treatment with diclofenac.
For validation of the expression profiles of IL1β and IL8, we analyzed the presence of the respective ILs in the supernatant of RASF after treatment with prednisolone ( Fig. 5) . IL1β was not detected in the supernatant of NDSF and was elevated in supernatants of RASF. Prednisolone repressed the expression of IL1β and resulted in decreased levels of IL1β in the supernatants of RASF. The level of IL8 was low in supernatants of NDSF and rose up to 6400 pg/ml in supernatants of RASF. Application of prednisolone lowered the level of IL8, reaching 3300 pg/ml in supernatants of RASF. This confirmed the expression profile of IL1β and IL8 as determined by gene expression analysis.
Screening for dominant pathways involved in drug action
The KEGG database was retrieved for the leading pathways with at least 5 genes changed upon drug exposure. Of all drugs investigated, MTX induced the most changes, with the highest number of genes (n = 14) changed in the cell cycle (hsa04110) and mitogen-activated protein kinase signaling (hsa04010), followed by cytokine-cytokine receptor interaction (hsa04060), pathways related to cell-cell and cell-matrix interaction (hsa04510, hsa01430, hsa04512), apoptosis (hsa04210), hematopoietic cell lineage (hsa04640,) and insulin signaling (hsa04910). Prednisolone changed the expression of up to 10 genes in the cytokinecytokine receptor interaction pathway collection, focal adhesion (hsa04510), extracellular matrix-receptor interaction (hsa04512), and hematopoietic cell lineage (hsa04640). Incubation with diclofenac revealed the least changes, with fewer than 5 genes in any of the 3 leading pathways: cytokine-cytokine receptor interaction, peroxisome proliferator-activated receptor signaling, and cell cycle. Details of the prominent changes by prednisolone and MTX are shown in Figure 6 , with only MTX-induced reduction of several cyclin genes known to regulate and promote cell proliferation (Fig. 6A) . In contrast, the proinflammatory mediators IL1, IL8, and CXCL3 were suppressed by prednisolone but found to be upregulated by MTX (Fig. 6B) . Transcripts for extracellular matrix products including collagens, laminin, and thrombospondin were increased after prednisolone and decreased after MTX exposure.
DISCUSSION
In the present study, we documented that antirheumatic drugs have distinct effects on the RA-related expression patterns in synovial fibroblasts. Treatment of RASF with MTX reversed the expression of disease-related genes known from cell growth, metabolism, apoptosis, and cell adhesion. Prednisolone repressed genes that were induced in RASF and that are related to inflammation. Diclofenac had no effect on the expression of genes differentially expressed in RASF compared to NDSF.
In RA, the inflamed synovial tissue plays an important role in joint inflammation and destruction. Global assessment of the gene expression profile of RA synovial tissue underlined its dual nature in RA. Recently, 2 groups of RA synovial tissues were reported with predominant expression of 1) genes of the adaptive immune system and 2) genes related to tissue remodeling with a low inflammatory gene expression signature. 17, 18 Therefore, activated synovial fibroblasts may play a crucial role in the onset of synovitis and potentially promote RA and joint destruction. Isolated and propagated RASF show enhanced, tumor-like proliferation activity, 19 have the capacity to invade cartilage in an severe combined immunodeficient (SCID) mouse model, 20 and may reflect the disease status of the synovial tissue from which they originated. 21 In this work, we took advantage of these growth properties of RASF and their pathophysiological relevance. To ensure standardization and comparability between different drugtesting experiments, we used immortalized synovial fibroblasts and determined the RA gene expression profiles that are reverted by the treatment with commonly used antirheumatic drugs.
Treatment with MTX resulted in the reduction of cell viability that may correlate with a decrease in proliferation activity of the cells. Similar effects of MTX on cell proliferation were also shown for synovial cells from patients with RA, osteoarthritis (OA), and other arthritides. 22 This antiproliferative effect of MTX was substantiated in our study by the reversion of the expression of IGFBP3, RAI3, DDIT4, and CAV2, genes that are related to proliferation and apoptosis. IGFBP3 is a carrier for insulin-like growth factors (IGF)-1 and -2 and plays an important role in proliferation and apoptosis of various cell types including tumor cells. 23 IGFBP3 was found reduced in sera of patients with RA and other arthritides but was elevated in sera of patients treated with glucocorticoids, NSAIDs, or DMARDs. 24, 25 Increased levels of IGF and IGFBP3 were also detected in the synovial fluid of patients with RA and OA compared to normal donors. 26, 27 Interestingly, IGFBP3 was repressed in RASF compared to NDSF and was induced upon treatment with MTX. Although it is unclear whether synovial fibroblasts contribute to the levels of IGFBP in synovial fluid or serum, the reduced expression of IGFBP3 in RASF may favor an IGF-mediated proliferation of cells in the inflamed RA synovium. MTX may exert its antiproliferative effect by directly regulating the IGF system through IGFBP or by inducing apoptosis as shown for RA synovial tissue in the SCID mouse model after oral treatment. 28 Treatment of immortalized RASF with MTX also affected regulation of the cell adhesion molecule ITGA6. ITGA6 is repressed in RASF and is induced after application of MTX. This is consistent with the reduced expression of ITGA6 in highly inflamed synovial tissue of RA patients and its induction in OA synovial fibroblasts after stimulation with proinflammatory cytokines such as TNF-α.
Remarkably, TNF-α repressed and MTX induced the expression of ITGA6 in long-term cultures of RASF. 29 Therefore, the loss of integrins in RASF may contribute to their evasion from inflamed synovial tissues prior to the formation of pannus tissue. Glucocorticoids, like prednisolone, are commonly used in the treatment of RA, effectively reduce disease activity in the short term, and may exert their anti-inflammatory effects by inhibiting proliferation and function of different cell types including fibroblasts and macrophages. 30 Here, prednisolone repressed the proinflammatory interleukins IL1β and IL8, which were elevated in RASF. ILs play an important role in the pathophysiology of RA. IL1β is elevated in RA synovial fluid, 31 and injection of IL1 transgenic synovial fibroblasts into rabbit joints induces arthritis. 32 In the mouse collagen induced-arthritis model, prednisolone reduced the expression of IL1β. 33 Treatment of RA patients with the human IL1 receptor antagonist (Anakinra) reduces disease activity and defers bone destruction. 34 IL8 may play an important role in cell infiltration and fibroblast activation in RA. This IL is elevated in inflamed compared to normal synovial tissue 35 and induces arthritis after infusion into rabbit joints. 36 IL8 has been shown to be produced predominantly by synovial macrophages, is released by synovial fibroblasts, and is elevated in the sera of RA patients. 37 These data are consistent with our results that document the induction of IL1β and IL8 in RASF and their repression upon prednisolone treatment.
Comparing molecular changes induced by prednisolone and MTX in general, KEGG pathway analysis revealed complex influences of MTX dominated by antiproliferative effects and of prednisolone with typical anti-inflammatory effects. Also important is the induction of proinflammatory mediators in the synovial fibroblasts by MTX, possibly as a response to stress. Such effects were also reported in the context of MTX pneumonitis. 38 These findings could explain the different clinical effects of treatment with respect to the kinetics of response and side effects. Whereas prednisolone reduces clinical symptoms of pain and inflammation within less than 24 h, patients receiving MTX often complain about side effects within this time frame after application. Furthermore, improvement will occur not earlier but within several weeks of MTX therapy, which could well correlate with a gradual reduction of cells involved in synovitis. MTX may reduce cell proliferation or induce apoptosis not only in fibroblasts but also in T cells and monocytes. 39 However, in lymphocytes, molecular effects of MTX may also involve suppression of activation and adhesion molecules. 40 NSAIDs, such as diclofenac, relieve pain of RA patients but have only limited effects on inflammation and disease progression. 41 Low doses of diclofenac had no effect on the growth properties of synovial fibroblasts or on the expression profile of disease-related genes. Although high doses of diclofenac had cytotoxic effects on RASF and NDSF, disease-related genes were not affected. An apoptotic effect on primary RASF has been reported for several NSAIDs, including high doses of diclofenac, which were accompanied by the activation of the peroxisome proliferator-activated receptor γ. 42 Moreover, diclofenac has been shown to target nonfibroblastic inflammatory cells by reducing the amount of polymorphonuclear cells in the synovial fluid in a rabbit antigen-induced arthritis model. 43 Thus, diclofenac may exert its RA-related effects on cell types infiltrating the synovium rather than on the synovial fibroblasts.
With respect to target validation, our in vitro system of synovial fibroblasts allows us to validate drug candidates that interfere with immune stimulation or cell proliferation or that affect tissue matrix formation. This validation could be performed using customized arrays with genes related to these pathways. Furthermore, for synovial fibroblast targeting, anti-inflammatory concepts seem to be more effective than antiproliferative mechanisms for a drug discovery approach. Metabolic inhibitors such as MTX may especially induce stress signaling and thus may increase acute side effects, which could be monitored in this system.
In conclusion, the expression of a distinct subset of RArelated genes in synovial fibroblasts is reverted by the treatment with frequently used antirheumatic drugs. Thus, gene expression profiling of immortalized synovial fibroblasts reflects pathophysiological mechanisms involved in rheumatoid synovitis and is a valuable tool in the study of antirheumatic drug effects. Furthermore, synovial fibroblasts are well suited for the screening of potential antirheumatic compounds that exhibit similar properties as DMARDs and SAIDs and may therefore support defining promising candidates for the treatment of RA.
